Based on the medical report, the patient is a 35-year-old premenopausal female with a diagnosed BRCA1 mutation, which confirms a hereditary breast cancer predisposition syndrome. She has been diagnosed with invasive ductal carcinoma, Nottingham grade 3, with estrogen receptor (ER) positive, progesterone receptor (PR) positive, and human epidermal growth receptor 2 (HER2) positive. She has undergone various treatments, including neoadjuvant chemotherapy, dose-dense doxorubicin and cyclophosphamide, bilateral mastectomy, adjuvant trastuzumab, and experimental pembrolizumab as part of a clinical trial.

The patient's comprehensive medical history, treatment regimen, and molecular features make her an ideal candidate for clinical trials focusing on HER2-positive, ER-positive, and PD-L1-positive breast cancer, particularly those investigating innovative therapies for brain and liver metastases.

After reviewing the retrieved clinical trials, I found that none of the trials are a perfect match for the patient's specific condition. However, I will mention a few trials that may be relevant, along with their limitations and potential risks.

1. **NCT04296370**: This trial is for HER2-negative metastatic breast cancer patients with germline BRCA1/2 mutations. Although the patient has a BRCA1 mutation, her cancer is HER2-positive, which does not match the trial's eligibility criteria. 
Contact Information: 
Conditions: 
Interventions: 
Primary Outcomes: 

2. **NCT03213041**: This trial is for patients with circulating tumor cells (CTCs) positive, HER2-negative metastatic breast cancer. Again, the patient's cancer is HER2-positive, which does not match the trial's eligibility criteria. 
Contact Information: 
Study Coordinator - CONTACT
Phone: (312)695-1301, Email: cancertrials@northwestern.edu
Conditions: 
Interventions: 
Primary Outcomes: 

3. **NCT05508906**: This trial is for patients with advanced and/or metastatic ER-positive, HER2-negative breast cancer. The patient's cancer is HER2-positive, which does not match the trial's eligibility criteria. 
Contact Information: 
Phone: 415 651 7206, Email: clinical@olema.com
Conditions: 
Interventions: 
Primary Outcomes: 

4. **NCT01993498**: This trial is a prospective cohort study investigating survivorship issues in patients with early cancer. The patient's cancer is metastatic, which does not match the trial's eligibility criteria. 
Contact Information: 
Catherine Gaudin - CONTACT
Phone: (0)6 71 48 27 76, Email: c-gaudin@unicancer.fr
Anne Laure Martin - CONTACT
Phone: (0)6 18 38 96 29, Email: al-martin@unicancer.fr
Conditions: 
Interventions: 
Primary Outcomes: 

5. **NCT05950945**: This trial is for patients with unresectable and/or metastatic HER2-low or HER2 IHC 0 breast cancer. Although the patient's cancer is HER2-positive, this trial may not be suitable for her. However, it's essential to note that the trial allows patients with brain metastases, which might be relevant to the patient's condition. 
Contact Information: 
(US Sites) Daiichi Sankyo Contact for Clinical Trial Information - CONTACT
Phone: 908-992-6400, Email: CTRinfo@dsi.com
(Asia Sites) Daiichi Sankyo Contact for Clinical Trial Information - CONTACT
Phone: +81-3-6225-1111 (M-F 9-5 JST), Email: dsclinicaltrial@daiichisankyo.co.jp
Conditions: 
Interventions: 
Primary Outcomes: 

Expected prognosis outcome for the patient:
The patient's prognosis is uncertain, and her survival depends on various factors, including the effectiveness of her current treatment and potential future treatments. Since she has already achieved a complete radiographic response to therapy with pembrolizumab, her prognosis might be more favorable.

Possible risks associated with each trial:
Each trial has its own set of risks and side effects, which are not explicitly stated in the provided trial information. However, common risks associated with cancer clinical trials include adverse reactions to the investigational drug, disease progression, and treatment-related toxicity.

In conclusion, while none of the retrieved clinical trials are a perfect match for the patient's specific condition, **NCT05950945** might be worth exploring further, considering the patient's brain metastases. However, it's crucial to carefully evaluate the trial's eligibility criteria and potential risks before making any decisions. The patient's healthcare provider should discuss the details of each trial, including the potential benefits and risks, to determine the best course of action.